miR-29b targets DNMT1, DNMT3A, and 3B in AML cell lines and primary AML blasts. (A) DNMT3A, (B) DNMT3B, and (C) DNMT1 mRNA expression after nucleoporation (K562, MV4-11) or infection (Kasumi-1) of pre-miR-29b or their respective controls (scrambled oligonucleotides for K562 and MV4-11cells and empty vector lentivirus for Kasumi-1 cells). Histograms show fold changes (reduction) in mRNA expression with respect to the controls after normalization with 18s in 3 independent experiments. Bars represent SD. (D) DNMT1, DNMT3A, and 3B protein expression after pre-miR-29b or control nucleoporation or infection in K562, MV4-11, and Kasumi-1 cell lines. Equivalent gel loading was confirmed by probing with antibodies against β-actin. (E) DNMT1 and DNMT3A and 3B mRNA expression in primary AML patient samples (n = 3) after nucleoporation of pre-miR-29b or a scrambled oligonucleotide. Histograms show fold changes (reduction) in mRNA expression with respect to the control after normalization with 18s. Bars represent SD.